These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14986269)

  • 1. Short-course beta-lactam treatment for community-acquired pneumonia.
    Stralin K; Sjöberg L; Holmberg H
    Clin Infect Dis; 2004 Mar; 38(5):766-7. PubMed ID: 14986269
    [No Abstract]   [Full Text] [Related]  

  • 2. Decrease in drug resistance in pneumococcal community-acquired pneumonia.
    Obando I; Arroyo L; Sanchez-Tatay D
    Chest; 2007 Jul; 132(1):359; author reply 359-60. PubMed ID: 17625101
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of beta-lactam agents in the treatment of community-acquired pneumonia.
    Garau J
    Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):83-99. PubMed ID: 15696306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 5. [Resistance to penicillin and erythromycin of Streptococcus pneumoniae and Streptococcus pyogenes isolated from community-acquired respiratory infections in Spain between 1986-1999 and its relationship with the use of beta-lactams and macrolides].
    Granizo Martínez JJ
    Rev Esp Quimioter; 2005 Mar; 18(1):83-5. PubMed ID: 15915241
    [No Abstract]   [Full Text] [Related]  

  • 6. [New quinolones for the treatment of community-acquired pneumonia--pro].
    Zimmerli S
    Dtsch Med Wochenschr; 2003 May; 128(19):1070. PubMed ID: 12736859
    [No Abstract]   [Full Text] [Related]  

  • 7. How much evidence do we have to recommend oral doxycycline for empirical treatment of community-acquired pneumonia?
    Bantar C
    Clin Infect Dis; 2004 Feb; 38(3):459-60. PubMed ID: 14727226
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia.
    Mufson MA; Stanek RJ
    Clin Infect Dis; 2006 Jan; 42(2):304-6. PubMed ID: 16355349
    [No Abstract]   [Full Text] [Related]  

  • 11. Antimicrobial resistance and treatment of community-acquired pneumonia.
    Mandell LA
    Clin Chest Med; 2005 Mar; 26(1):57-64. PubMed ID: 15802166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of lower respiratory tract infections in immunocompetent adults (community-acquired pneumonia and acute exacerbation of chronic obstructive pulmonary disease): the challenge of a new consensus conference].
    Chidiac C
    Med Mal Infect; 2006 Jan; 36(1):1-3. PubMed ID: 16413722
    [No Abstract]   [Full Text] [Related]  

  • 13. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.
    File TM
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S17-26. PubMed ID: 11810607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibiotic therapy for community acquired Streptococcus pneumoniae pneumonia: clinical relevance of antibiotic resistance].
    Bédos JP; Bruneel F
    Med Mal Infect; 2006; 36(11-12):667-79. PubMed ID: 16842956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
    Lee WK; Young BW
    J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W; Assawasanti K; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.